ll-37 research peptide FAQ

This is mechanistically rational if your model involves both infection and excessive inflammation—LL-37 handles pathogen clearance while KPV dampens cytokine storm. Administer them separately or in sequence rather than mixing in the same vial, as their optimal pH and concentration ranges differ. Sequential dosing (LL-37 first for antimicrobial action, KPV second for inflammation control) mirrors physiological immune response timing.

KPV will not reduce bacterial load or colony-forming units because it has no antimicrobial mechanism. You may observe reduced inflammatory cytokine levels if the immune response generates significant TNF-α or IL-1β, but pathogen clearance will remain unchanged. If your endpoint is CFU reduction, membrane permeability, or time-to-kill kinetics, KPV is the wrong tool—switch to LL 37 for direct antimicrobial activity.

Cloudiness indicates peptide aggregation, which reduces biological activity in antimicrobial assays. LL-37 aggregates at concentrations above 5 mg/mL, especially in neutral or alkaline pH. Reconstitute at lower concentration (1–2 mg/mL) in slightly acidic bacteriostatic water (pH 5–6), vortex gently, and aliquot immediately. Aggregated LL-37 may still retain some activity but produces inconsistent results across replicates.

Both peptides undergo significant degradation at room temperature within 6–8 hours due to protease contamination in bacteriostatic water and spontaneous peptide bond hydrolysis. Expect 30–50% loss of activity after 24 hours at 20–25°C. Refrigerate immediately after reconstitution at 2–8°C, and prepare single-use aliquots to avoid repeated freeze-thaw cycles, which denature peptide structure further.

Partial response suggests the inflammatory pathway involves mediators beyond NF-κB—potentially MAPK (mitogen-activated protein kinase) pathways, NLRP3 inflammasome activation, or Th17-driven inflammation. KPV specifically inhibits NF-κB translocation but doesn't suppress alternative inflammatory cascades. Consider dose escalation (10 μM to 100 μM) or combination with pathway-specific inhibitors to isolate which inflammatory mechanism dominates your model.